Gilead Sciences
Gilead Sciences, Inc., a leading biopharmaceutical company headquartered in the United States, has been at the forefront of innovative healthcare since its founding in 1987. With a strong presence in regions such as Europe and Asia, Gilead focuses on the research, development, and commercialisation of antiviral drugs, particularly for HIV, hepatitis B, hepatitis C, and influenza. The company is renowned for its groundbreaking therapies, including Biktarvy and Harvoni, which have transformed the treatment landscape for chronic viral infections. Gilead's commitment to advancing medicine is underscored by its significant achievements, including multiple FDA approvals and a robust pipeline of investigational therapies. As a key player in the biopharmaceutical industry, Gilead Sciences continues to shape the future of healthcare through its dedication to scientific innovation and patient care.
DitchCarbon Score
How does Gilead Sciences's carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Research Services industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
Gilead Sciences's score of 58 is higher than 99% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Let us know if this data was useful to you
Gilead Sciences's reported carbon emissions
In 2023, Gilead Sciences reported total greenhouse gas (GHG) emissions of approximately 1,179,800,000 kg CO2e, with emissions distributed across various scopes: 56,096,000 kg CO2e from Scope 1, 80,000 kg CO2e from Scope 2, and a significant 1,121,798,000 kg CO2e from Scope 3. This represents a slight decrease in Scope 1 emissions from 2022, which were about 55,919,000 kg CO2e, while Scope 3 emissions decreased from approximately 1,202,703,000 kg CO2e in the previous year. Gilead has set ambitious climate commitments, aiming to reduce its Scope 1 and 2 GHG emissions by 25% by 2025, using a 2016 baseline. Furthermore, the company has committed to achieving carbon net-zero operational GHG emissions by 2030. This includes a more aggressive target to reduce Scope 1 and 2 emissions by 46% by 2030 from a 2019 baseline, alongside a 15% reduction in Scope 3 emissions over the same timeframe. These initiatives align with Gilead's broader environmental strategy, reflecting a commitment to sustainability within the pharmaceutical and biotechnology sector. The company is actively working towards these targets to mitigate its environmental impact and contribute to global climate goals.
Unlock detailed emissions data
Access structured emissions data, company-specific emission factors, and source documents
| 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | |
|---|---|---|---|---|---|---|---|---|
| Scope 1 | 44,754,000 | 00,000,000 | 00,000,000 | 00,000,000 | 00,000,000 | 00,000,000 | 00,000,000 | 00,000,000 |
| Scope 2 | 36,813,000 | 00,000,000 | 00,000,000 | 00,000,000 | 00,000,000 | 00,000,000 | 00,000,000 | 00,000,000 |
| Scope 3 | - | - | - | 0,000,000,000 | 0,000,000,000 | 0,000,000,000 | 0,000,000,000 | 0,000,000,000 |
Industry emissions intensity
Location emissions intensity
Reduction initiatives & disclosure networks
Companies disclose and commit to reducing emissions to show they are serious about reducing emissions impact over time. They can also help a company track its progress over time.
Gilead Sciences is participating in some of the initiatives that we track. This may change over time as the company engages with new initiatives or updates its commitments. DitchCarbon will update this information as it becomes available.
